Transgene S.A.. (4/10/17). "Press Release: Transgene Announces Upcoming Investor Meetings and R&D Day". Strasbourg.

	Region	Amsterdam
	Country	Netherlands
	Organisation	Transgene S.A. (Euronext: TNG)
	Group	Mérieux (Group)
	Organisation 2	Kempen & Co. N.V.
	Group	Van Lanschot (Group)
	Product	Kempen Life Sciences Conference 2017 Amsterdam
	Product 2	TG4010 (MVA-MUC1-IL2) (Transgene)
	Index term	Mérieux–Van Lanschot: investor conference, 201704 supply service Transgene SA presents at Kempen Life Sciences Conference
	Index term 2	Mérieux–Kepler Chevreux: investor conference, 201706 supply service Transgene SA presents at Kepler Biotech Days 2017 in Paris
	Person	Larguier, Lucie (Mérieux 201704 Director CorpComm + IR at Transgene before Citigate Dewe Rogerson Paris)
	Person 2	Perrier, Marine (Enterome 202103 Head of External Communications + IR before Citigate Dewe Rogerson)

Transgene today announced that management will participate in the upcoming investor events set out below.

• Kempen 10th Life Sciences Conference: April 19, 2017 - Amsterdam, Netherlands

• Kepler Biotech Days: June 9, 2017 - Paris, France

Transgene will host a “R&D Day”, on June 22, 2017 in Paris, France. The event which will be conducted in English will feature presentations from several leading international scientists and clinicians.

Next scheduled financial communication
1st quarter 2017 business update
April 25, 2017 after market close

Contacts

Transgene:
Lucie Larguier
Director Corporate Communications & IR
+33 (0)3 88 27 91 04
investorrelations@transgene.fr

Media contacts: Citigate Dewe Rogerson
David Dible / Marine Perrier
+ 44 (0)20 7638 9571
transgene@citigatedr.co.uk

About Transgene

Transgene S.A. (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010, a therapeutic vaccine for non-small cell lung cancer and Pexa-Vec, an oncolytic virus for liver cancer. The Company has several other programs in clinical and preclinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China. Additional information about Transgene is available at www.transgene.fr.

Follow us on Twitter: @TransgeneSA

Record changed: 2023-06-05